ALLMedicine™ Hemolytic Uremic Syndrome Center

May 6th, 2021 - Patients with atypical hemolytic uremic syndrome (aHUS) have long been considered ineligible for kidney transplantation (KTx) in several centers due to the high risk of disease recurrence, graft loss and life-threatening complications. The availab...

Apr 30th, 2021 - Enterohaemorrhagic E. coli cause major epidemics worldwide with significant organ damage and very high percentages of death. Due to the ability of enterohaemorrhagic E. coli to produce shiga toxin these bacteria damage the kidney leading to the he...

Apr 26th, 2021 - We report a fatal case of hemolytic uremic syndrome with urinary tract infection in Japan caused by Shiga toxin-producing Escherichia coli. We genotypically identified the isolate as OX18:H2. Whole-genome sequencing revealed 3 potentially pathogen...

Apr 19th, 2021 - Atypical hemolytic uremic syndrome (aHUS) is a rare but critical illness. To this date, few studies have reported on the disease in Chinese children. We studied a Chinese pediatric cohort to delineate the clinical characteristics, genotypes, and p...

Apr 16th, 2021 - Shiga toxin-producing Escherichia coli (STEC) are among common foodborne bacterial pathogens and healthy livestock are the main source of this bacterium. Severe diseases attribute to two types of cytotoxin Stx1 and Stx2, which are also called Shig...

Apr 4th, 2019 - As of April 4, 2019, 72 people infected with the outbreak strain of E. coli O103 have been reported from five states. Eight people have been hospitalized. No cases of hemolytic uremic syndrome (HUS) or deaths have been reported.

Jul 16th, 2016 - Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. In 2013, we developed diagnostic criteria to enable early diagnosis and timely ...

Apr 10th, 2015 - Atypical hemolytic uremic syndrome (aHUS) emerged during the last decade as a disease largely of complement dysregulation. This advance facilitated the development of novel, rational treatment options targeting terminal complement activation, e.g....

Aug 7th, 2014 - Guidelines for the management and investigation of hemolytic uremic syndrome.|2014|Igarashi T,Ito S,Sako M,Saitoh A,Hataya H,|standards,diagnosis,etiology,therapy,standards,

Dec 17th, 2013 - Atypical hemolytic uremic syndrome (aHUS) is rare and comprises the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Recently, abnormalities in the mechanisms underlying complement regulation have been focused...

May 6th, 2021 - Patients with atypical hemolytic uremic syndrome (aHUS) have long been considered ineligible for kidney transplantation (KTx) in several centers due to the high risk of disease recurrence, graft loss and life-threatening complications. The availab...

Apr 30th, 2021 - Enterohaemorrhagic E. coli cause major epidemics worldwide with significant organ damage and very high percentages of death. Due to the ability of enterohaemorrhagic E. coli to produce shiga toxin these bacteria damage the kidney leading to the he...

Apr 26th, 2021 - We report a fatal case of hemolytic uremic syndrome with urinary tract infection in Japan caused by Shiga toxin-producing Escherichia coli. We genotypically identified the isolate as OX18:H2. Whole-genome sequencing revealed 3 potentially pathogen...

Apr 19th, 2021 - Atypical hemolytic uremic syndrome (aHUS) is a rare but critical illness. To this date, few studies have reported on the disease in Chinese children. We studied a Chinese pediatric cohort to delineate the clinical characteristics, genotypes, and p...

Apr 19th, 2021 - Soliris is a complement inhibitor indicated for: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis (1.1). The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-med...

Oct 20th, 2019 - The US Food and Drug Administration (FDA) has approved ravulizumab (Ultomiris, Alexion Pharmaceuticals) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adults and children age 1 month or older with atypical hemolytic uremic synd...

Jun 5th, 2019 - Hemolytic uremic syndrome (HUS) is a rare illness that can be acquired through the consumption of food products contaminated with strains of Shiga toxin-producing Escherichia coli (E coli ; STEC). 1 Between 6% and 15% of individuals infected with.

Jun 1st, 2019 - Click here to access June 2019 Management of Neurologic Disorders in Federal Health Care Table of Contents Early and Accurate Identification of Parkinson Disease Among US Veterans Proton Pump Inhibitor Use and Risk of Dementia in the Veteran Popul.

Apr 4th, 2019 - As of April 4, 2019, 72 people infected with the outbreak strain of E. coli O103 have been reported from five states. Eight people have been hospitalized. No cases of hemolytic uremic syndrome (HUS) or deaths have been reported.

Sep 14th, 2018 - Henrique Orlandi Mourao Hairy cell leukemia Image from Paulo The U. S.